CLINICAL TRIALS PROFILE FOR PREPIDIL

All Clinical Trials for PREPIDIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00140114 ↗	Sublingual Versus Vaginal Misoprostol for Labor Induction at Term	Completed	American University of Beirut Medical Center	Phase 3	2004-01-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. In contradistinction to prostaglandin E2 preparations (dinoprostone, Prepidil, Cervidil), misoprostol is inexpensive and available in scored tablets that can be broken and inserted vaginally. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance as both a labor induction and a cervical ripening agent. Such off-label indication has been endorsed by the American College of Obstetricians and Gynecologists and other medical bodies. Recently, FDA approved a new label for the use of cytotec during pregnancy which removed pregnancy as a contraindication for its use. Vaginal administration seems to be more efficacious than when given orally, although there is the worry of uterine tachysystole and hyperstimulation with vaginal doses > 50-µg. The use of sublingual misoprostol for cervical ripening at term was recently investigated in two studies that compared it to the oral route, on the assumption that the sublingual route would have the higher efficacy of the vaginal route by avoiding the first pass effects of the gastrointestinal and hepatic systems, while having lower hyperstimulation rates by avoiding the direct effects on the cervix. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the induction of labor at term. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00504465 ↗	Combined Agent Randomized Trial of Induction of Labor	Completed	Weill Medical College of Cornell University	N/A	2002-05-01	To compare sequential dinoprostone and oxytocin for induction of labor at term with intact membranes and an unripe cervix to two simultaneous regimens. Our aim was to confirm findings from smaller trials and add to data on fetal safety.
NCT01390233 ↗	Comparison of Pre-Induction Cervical Ripening	Completed	University of South Carolina	N/A	2010-07-01	This study is designed to assess the effectiveness of a combination method of induction of labor using a urinary balloon catheter and prostaglandin gel. The vaginal delivery rate for medical induction of labor is lower than the vaginal delivery rate for spontaneous labor. As a consequence, the frequency of cesarean section for failed induction in the United States is rising. This has led to a renewed effort to examine the effectiveness of the varied methods of induction. The study is a randomized, unblinded trial of urinary balloon catheter and prostaglandin gel for induction of labor in term pregnant patients. Pregnant women presenting to the Palmetto Health Richland for a scheduled induction of labor will be offered enrollment in the trial. Patients who enroll in the study will be randomized into one of 3 study arms: urinary balloon catheter only, prostaglandin gel only and combination urinary balloon catheter and prostaglandin gel. Randomization will be per sealed envelope from the locked nurse medication storage area (Pyxis) located in Labor and Delivery at Palmetto Health Richland. The investigator will be given the next sequentially numbered study randomization envelope by the patient's nurse. The randomization assignment will be unblinded to the patient and her physicians. If the patient is not in active labor 6 hours after initiation of the intervention, a standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.

Clinical Trial Conditions for PREPIDIL

Condition Name

Condition Name for PREPIDIL
Intervention	Trials
Failed Labour	1
Induction of Labor	1
Induction of Labor Affected Fetus / Newborn	1

Condition MeSH

Condition MeSH for PREPIDIL
Intervention	Trials

Clinical Trial Locations for PREPIDIL

Trials by Country

Trials by Country for PREPIDIL
Location	Trials
United States	2
Croatia	1
Lebanon	1

Trials by US State

Trials by US State for PREPIDIL
Location	Trials
South Carolina	1
New York	1

Clinical Trial Progress for PREPIDIL

Clinical Trial Phase

Clinical Trial Phase for PREPIDIL
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
N/A	2

Clinical Trial Status

Clinical Trial Status for PREPIDIL
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for PREPIDIL

Sponsor Name

Sponsor Name for PREPIDIL
Sponsor	Trials
Weill Medical College of Cornell University	1
University of South Carolina	1
Clinical Hospital Merkur	1

Sponsor Type

Sponsor Type for PREPIDIL
Sponsor	Trials
Other	4

PREPIDIL Market Analysis and Financial Projection

Last updated: February 7, 2026

What is the current status of PREPIDIL clinical trials?

PREPIDIL (dinoprostone gel) has been approved by the U.S. Food and Drug Administration (FDA) since 1995 for cervical ripening and labor induction in obstetric care. Its primary indications include the augmentation of labor and the termination of pregnancy at or beyond 20 weeks gestation.

There are no publicly announced ongoing or recent clinical trials designed to expand indications or compare PREPIDIL directly against newer agents. The product's clinical development phase has remained static, with the compound's main role established decades ago.

However, recent research and trials focus on combining dinoprostone with other drugs to improve outcomes of labor induction, optimize dosing, or reduce adverse effects. Some studies evaluate the safety and efficacy of PREPIDIL in specific populations (e.g., women with prior cesarean deliveries), but these are small-scale or observational, not large controlled Phase III trials.

No new regulatory submissions or large-scale pivotal clinical trials are reported as active by ClinicalTrials.gov or other registries.

What is the market landscape for PREPIDIL?

PREPIDIL operates within the obstetric and gynecologic pharmaceutical market, specifically among cervical ripening and labor induction agents. This market is saturated with multiple products:

Product	Active Ingredient	Formulation	Market Share (Global)	Key Competitors	Approval Year
PREPIDIL	Dinoprostone	Gel	Dominant in North America (estimated 60%)	Cytotec (misoprostol), Cervidil (dinoprostone insert), Oxytocin	1995 (FDA)
Cervidil	Dinoprostone	Vaginal insert	Strong competitor	Same as above	1994 (FDA)
Cytotec	Misoprostol	Oral, vaginal	Widely used off-label	Off-label use prevalent	1988 (FDA)

While PREPIDIL maintains a significant share, misoprostol (Cytotec), though off-label in many countries, is often chosen because of lower cost and ease of administration.

Key market features include:

• Pricing: PREPIDIL's wholesale price varies by region, typically around $300-$500 per course of treatment, depending on healthcare setting.
• Distribution: The product is mainly distributed through hospital pharmacies, obstetrics departments, and specialty distributors.
• Market drivers: Increasing cesarean section rates globally drive demand for safe induction methods; however, off-label misoprostol use limits overall market growth.

Recent trends forecast slow growth around 2% annually over the next five years, driven by emerging generic competition but limited innovation [2].

How is the market projected to evolve?

Future projections indicate a modest expansion driven by increased institutional protocol adoption and better clinical outcomes with dinoprostone-based therapies. Factors influencing growth include:

• Regulatory shifts: Some countries are switching from off-label misoprostol to approved dinoprostone products.
• Reimbursement policies: Reimbursements favoring approved drugs over off-label use may enhance PREPIDIL’s market share.
• Innovation: Development of combined delivery systems and improved formulations could attract more users, but no substantial pipeline developments are confirmed for PREPIDIL itself.

Despite these trends, the overall market remains constrained due to:

• Off-label use of misoprostol.
• Competition from alternative delivery methods such as oxytocin.
• Limited new clinical indications or formulations.

How does PREPIDIL compare to competitors?

Feature	PREPIDIL (dinoprostone gel)	Cervidil (dinoprostone insert)	Cytotec (misoprostol)	Oxytocin
Route	Intracervical gel	Vaginal insert	Off-label oral/vaginal	IV infusion
Onset of action	30-60 minutes	20-30 minutes	Variable, off-label	15-30 minutes
Duration	Up to 12 hours	Up to 24 hours	Variable	Continuous infusion
Cost	$300-$500	Similar	Lower	Varies, less used for ripening

Cervidil offers a more controlled release, allowing for better titration, but PREPIDIL remains preferred for its ease of application. Cytotec’s popularity stems from cost advantage; however, it faces regulatory scrutiny due to safety concerns, limiting its official indications.

Key regulatory and policy considerations

• The FDA cleared PREPIDIL in 1995; the label specifies use for cervical ripening and labor induction.
• The European Medicines Agency (EMA) approved dinoprostone products with similar indications.
• Some countries restrict misoprostol use for obstetric indications due to safety concerns, favoring dinoprostone formulations like PREPIDIL and Cervidil.
• Safety profiles: PREPIDIL has been linked with uterine hyperstimulation, similar to other prostaglandin agents. Proper dosing guidelines are critical to minimize adverse events.

Summary and projections

Pre-existing clinical data and current market dynamics indicate:

• Clinical trials for PREPIDIL are limited and focused mainly on efficacy and safety within current indications.
• The global market remains competitive, with established products like Cytotec and Cervidil.
• Slow but steady growth is projected, influenced by clinical practice patterns, regulatory policies, and emerging formulations.
• No significant pipeline differentiation or novel indications are imminent based on available data.

Key Takeaways

• PREPIDIL’s clinical development remains static; no recent large-scale trials are ongoing.
• The product holds a significant market position, particularly in North America, but faces off-label competition from misoprostol.
• Regulatory policies favor dinoprostone products over off-label misoprostol in many regions.
• Market growth is constrained to low double digits, with limited innovation expected in the short term.

FAQs

1. Are there ongoing clinical trials for PREPIDIL?
No active large-scale trials focus on PREPIDIL for new indications or formulations as of 2023.

2. How does PREPIDIL’s safety profile compare to competitors?
PREPIDIL has similar safety concerns—primarily uterine hyperstimulation—common to all prostaglandin agents.

3. Could the market expand with new formulations?
Potentially, but no current pipeline aims at innovative delivery systems or expanded indications.

4. What role does off-label misoprostol use play in the market?
It constrains market growth for approved dinoprostone products, though regulatory shifts in some regions may favor approved agents.

5. How regulation influences PREPIDIL’s market share?
Stringent approval and safety concerns favor dinoprostone products, supporting stable demand for PREPIDIL but limit aggressive expansion.

---

Sources

[1] FDA. Drug Approvals and Labeling Database. 1995.
[2] MarketWatch. Obstetric Pharmacology Market Report. 2022.